Epizyme Inc

Epizyme is a late-stage biopharmaceutical company that is focused on the treatment for people with cancer and other diseases through the discovery, development, and commercialization of epigenetic medicines. The company's lead product candidate, tazemetostat, is an oral, selective small molecule inhibitor of the EZH2 histone methyltransferase for the treatment of a range of cancer types in multiple treatment settings, and its G9a program, EZM8266, is used for the treatment of sickle cell disease. The company owns the global development and commercialization rights to tazemetostat outside of Japan. Eisai Co. Ltd holds the rights to develop and commercialize tazemetostat in Japan.
  • TickerEPZM
  • ISINUS29428V1044
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Wedbush Research

Wedbush Morning Call - May 26 2020 6:20AM

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Matthew Barcus
  • Robert Driscoll

AACR II 2020 Abstract Roundup for Covered Companies

Wedbush Research

Wedbush Morning Call - May 18 2020 6:54AM

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The Only Thing We Have To Fear Is Fear Itself This powerful quote from FDR can be applied to many facets of life. When it comes to the market, fear can lead investors to buy when it is time to sell, sell when it is time to buy, or freeze up altogether. Step one in conquering this issue starts with preparation and a gameplan. In our report from last Thursday (3/12) titled “Searching For A Bottom” we laid out our gameplan and what we need to see before having confidence that equity markets are bottoming. Below we provide new data points and observations. Yes, equities remain deeply oversold and...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

1 director sold

A director at Epizyme Inc sold 104,944 shares at 13.082USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Wedbush Research

Wedbush Morning Call - May 26 2020 6:20AM

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Matthew Barcus
  • Robert Driscoll

AACR II 2020 Abstract Roundup for Covered Companies

Wedbush Research

Wedbush Morning Call - May 18 2020 6:54AM

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

An unfavourable environment weighs on EPIZYME, which sees a downgrade to Negative

The independent financial analyst theScreener just requalified the general evaluation of EPIZYME (US), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Negative. As of the analysis date May 12, 2020, the closing price was USD 17.56 and its target price was estimated at USD 11.28.

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

ValuEngine Rating and Forecast Report for EPZM

ResearchPool Subscriptions

Get the most out of your insights

Get in touch